Jointown subsidiary gets marketing approval for Glycopyrronium Bromide

Jointown Pharmaceutical Group Co., Ltd. announced that its subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received marketing approval for Glycopyrronium Bromide from the National Medical Products Administration on October 16, 2025. The approval, valid until October 15, 2030, signifies compliance with drug registration requirements for domestic production of chemical raw material drugs. Glycopyrronium Bromide is a quaternary ammonium anticholinergic drug used for gastrointestinal and respiratory conditions.

This approval is expected to positively impact Jointown's pharmaceutical manufacturing self-produced business by enriching its product line and enhancing market competitiveness in raw materials. The company’s pharmaceutical manufacturing business generated sales revenue of CNY 1.593 billion in the first half of 2025, marking a 10.77% year-on-year increase.

Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. has invested approximately CNY 7.23 million in research and development for this product. The Glycopyrronium Bromide injection formulation, along with other variants, is already listed in the medical insurance catalog. Sales data from 2024 showed Glycopyrronium Bromide injection hospital sales reached CNY 53.5772 million, with a 38.29% increase. First-half 2025 sales were CNY 37.407 million, up 79.21%.